Anti-inflammatory role of fenofibrate in treating diseases

Biomol Biomed. 2023 May 1;23(3):376-391. doi: 10.17305/bb.2022.8534.

Abstract

Inflammation contributes to the pathogenesis of several diseases. Fenofibrate, known as a peroxisome proliferator-activated receptor - α (PPAR-α) agonist, is a classic drug for treating hyperlipidemia. In addition to its lipid-lowering effect, fenofibrate has also been reported to exert anti-inflammatory effects with complicated underlying mechanisms of action. In general, the anti-inflammatory effect of fenofibrate is secondary to its lipid-lowering effect, especially for the inflammation caused by hyperlipidemia in the circulatory system. Some anti-inflammatory actions may also come from its regulatory effects on intracellular lipid metabolism by activating PPAR-α. In addition, some roles in anti-inflammation might be mediated by its direct regulation of inflammatory signaling pathways. In order to understand anti-inflammatory activities and the underlying mechanisms of fenofibrate action in disease better, we herein reviewed and discussed the anti-inflammatory roles and its subserving mechanisms in various diseases of different organ systems. Thus, this review offers insights into the optimal use of fenofibrate in the clinical setting.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents / pharmacology
  • Fenofibrate* / pharmacology
  • Humans
  • Hyperlipidemias* / drug therapy
  • Inflammation / drug therapy
  • Lipids / therapeutic use
  • PPAR alpha / metabolism

Substances

  • Fenofibrate
  • PPAR alpha
  • Anti-Inflammatory Agents
  • Lipids